David Lebowitz
Stock Analyst at Citigroup
(1.58)
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
SDGR Schrodinger | Downgrades: Neutral | 35 20 | 18.61 | 7.47% | 10 | Aug 15, 2025 | |
ASND Ascendis Pharma | Maintains: Strong Buy | 243 290 | 195.94 | 48% | 14 | Aug 8, 2025 | |
CYTK Cytokinetics | Maintains: Buy | 80 77 | 33.2 | 131.93% | 3 | Aug 8, 2025 | |
INCY Incyte | Maintains: Strong Buy | 88 103 | 79.21 | 30.03% | 6 | Jul 30, 2025 | |
VKTX Viking Therapeutics | Maintains: Neutral | 31 38 | 38.19 | -0.5% | 2 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 15 22 | 10.93 | 101.28% | 4 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 58 67 | 48.24 | 38.89% | 5 | Jul 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Neutral | 83 129 | 129.46 | -0.36% | 6 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 45 56 | 37.43 | 49.61% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 14 10 | 10.75 | -6.98% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 2 | 1.69 | -11.24% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 67 64 | 40.84 | 56.71% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Sell | 32 45 | 43.3 | 3.93% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 65 68 | 65.86 | 3.25% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 70 | 20.01 | 249.83% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 382 | 349.43 | 9.32% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 103 96 | 56.8 | 69.01% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 18 12 | 3.23 | 271.52% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 170 164 | 434.89 | -62.29% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 36 39 | 14.19 | 174.84% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 20 21 | 12.5 | 68% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 435 405 | 3.73 | 10757.91% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 13 14 | 0.84 | 1566.67% | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 324 300 | 1.4 | 21328.57% | 2 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 10 5 | 1.47 | 240.14% | 2 | Aug 10, 2021 |